Hidden Per-Variant Costs When Scaling CFPS Across Liquid Handling Platforms

Cell-free protein synthesis for high-throughput variant screening runs straight from DNA or PCR template, so each construct can be tested without transforming and culturing cells. For campaigns on liquid-handling robots, the useful cost measure is the expense per interpretable variant result, which includes costs beyond the reagent price per reaction. Dead volume, lysate lot variability, template preparation, and dispense inefficiencies widen that gap, making campaign-level accounting essential to reagent and platform selection.

Why the headline reagent price per reaction is the wrong number to optimize

CFPS offers a genuine advantage for parallel screening. Reactions complete in hours rather than days, tolerate cytotoxic targets, and scale from microliter droplets to liter bioreactors. Linear expression templates also skip the tedious cloning steps, which makes broad libraries easier to test. These advantages explain the appeal of CFPS, but they do not establish the cost of obtaining a usable result from every construct.

A purchased reaction is not an interpretable variant result. Once small-molecule energy components are optimized, most of the cost is in lysate and DNA template, so there is less room to save on the other reagent ingredients. Kritharis et al. (ACS Synth Biol, 2026) identify high reagent costs and inconsistent product yields as significant barriers to industrial adoption. Yield inconsistency needs to be counted in the cost as well as treated as a technical concern.

How dead volume and dispense geometry silently consume reagent before a reaction runs

Lysate left in reservoirs, channels, or tips is purchased reagent that never enters a reaction. Reagent can be lost each time a reservoir is filled or a tip is loaded, no matter how many variants yield usable data. In a high-throughput campaign, the relevant consumption is therefore not just the sum of the nominal well volumes. It also includes the reagent required to make those volumes dispensable.

Miniaturization changes the balance between those two quantities. Moving from 96-well to 384-well to 1536-well formats reduces reaction volume per well, but does not proportionally reduce the dead volume associated with a liquid-handling head, reservoir, or tubing. More reagent types and repeated loading events create further opportunities for loss across a campaign.

Contact dispensers, acoustic dispensers such as Labcyte Echo, and syringe-based robots have different dead volume profiles and minimum accurate dispense volumes. At sub-microliter volumes, dispensing error can also turn a small reagent saving into a failed reaction or false negative. The practical audit is therefore specific to the setup. It should compare how much reagent is purchased and dispensed with the planned plate format and loading geometry, and check whether the chosen volume can be delivered accurately.

Why lysate lot variability is a per-campaign fixed cost, not a quality control problem

A new lysate lot creates a calibration obligation. When that lot enters mid-campaign, the calibration run consumes reactions, lysate, and time before producing a result for any queued variant. Its expense is a fixed charge associated with the lot transition, spread across the variants that depend on it. When the charge is counted only as quality control, it is left out of the screening budget. It is part of the cost of making results comparable.

This is not simply a user-error problem. Cell extract and plasmid batches vary, while pipetting, mixing, and instruments introduce further differences. Uncontrolled lysate activity can distort the apparent rank order of a library, making a variant look weaker because it was expressed in a less active aliquot. A low signal then becomes ambiguous. Resolving that ambiguity requires additional work, so the economic penalty extends beyond the initial calibration reactions.

The PURE system uses individually purified components and offers stronger lot-to-lot consistency than crude extract, but its per-reaction expense can make large-scale screening prohibitive. Within an extract-based workflow, published lot-level QC data provides a more limited intervention by making lot boundaries visible before they confound results. OpenCFPS™ publishes such data as a design requirement. That documentation can reduce the re-run burden caused by discovering a lot change only after screening has begun.

DNA template overhead as a line item that scales with library breadth, not reaction volume

Each distinct variant needs its own template, so reducing the amount of lysate dispensed does not proportionally reduce the work required to supply the library. Miniaturization can lower reaction consumption while leaving template preparation and QC largely intact. This distinction becomes more pronounced as a campaign expands to hundreds or thousands of variants. The template pipeline becomes a separate cost center and throughput constraint, neither of which appears in a kit’s per-reaction price.

Template quality also affects the value of every reaction. Purity and concentration must be consistent across the plate, because an under-concentrated or degraded template can produce a false negative. Without re-expression, that result can be indistinguishable from genuinely inactive material. The resulting expense is charged to the affected variant. A campaign budget that records template preparation but omits template-related re-expression therefore captures only part of this input’s cost.

A problem with the template can waste a lysate reaction that would otherwise work, while inconsistent lysate can cast doubt on a sound template. Reducing either input’s unit cost leaves that diagnostic dependency in place. Template synthesis and QC need to remain a distinct per-variant line item, even when reactions are heavily miniaturized. Re-expression events also need a place in the accounting, because they reveal whether savings in reaction volume are being spent again on uncertain results.

How platform-specific dispense inefficiencies compound with biological variability at scale

Poor dispense performance can erode reagent savings during the workflow. Accurate delivery of small amounts into numerous wells is essential because each well contains the entire reaction for its variant. When dispense variability and lysate variability occur together, however, their costs are not independent. A failed well may require another template aliquot and another lysate reaction, with the repeat also incurring the platform’s loading losses. The failure links expenses that look separate in a purchasing spreadsheet.

Timing creates another source of ambiguity. CFPS components added out of sequence or after a delay can compromise yield without revealing the cause at the plate-reading stage. Many liquid-handling platforms built for broad use make it hard to access gantry motion profiles, pipetting speeds, or task scheduling for custom experiments timed to the biology. University College London’s “Foehn” open-hardware system (2026) was designed to address the scalability bottleneck of sequential robot operations through asynchronous scheduling. Its purpose illustrates why automation capacity depends on the sequence of operations.

A failed well does not identify its cause. Dead volume starvation, a less active lysate aliquot, a template concentration anomaly, or a timing artifact can all complicate interpretation. Without lot-level and run-level data, the investigator cannot reliably allocate the failure to one source. The repeat is then charged at the full per-variant cost. Fixing nominal dispense volume alone leaves the biological and timing uncertainty unresolved.

Reagents also need to be checked for how well they work with automation. Standardized viscosity, predictable pipetting behavior, and documented component interactions are relevant criteria because they reduce ambiguous failures. OpenCFPS’s documented formulations are relevant to this evaluation, rather than a substitute for auditing the particular robot and workflow. Neither mechanical precision nor reagent consistency can be assessed in isolation from the other. Realizing the savings predicted from smaller reactions requires mechanical precision and reagent consistency to work together.

Why cost only becomes visible when all four drivers are tracked together across a campaign

A useful campaign ledger connects consumption to interpretable results. Purchased lysate volume and dispensed lysate volume establish the dead volume ratio, while lot identifiers connect calibration reactions to the variants that depend on them. Template synthesis and QC costs belong against each variant. Failed-well re-runs need both a rate and a fully loaded cost. Together, these records distinguish the expense of preparing the campaign from the expense of recovering results that the first pass did not produce.

For a pilot campaign, teams should keep those quantities in the same record. The calibration entry should record how many reactions and how much lysate are used at each lot boundary. The template entry should preserve preparation and QC costs per variant, while re-expression events should remain visible in the re-run record. Allocating shared campaign expenses across interpretable variant results then gives a more useful denominator than the number of reactions purchased.

Dead volume raises effective lysate consumption before any reaction runs, and calibration consumes more lysate before library results are produced. Template overhead remains even as well volumes shrink. Dispense-related repeats then consume inputs again, so counting only the replacement reaction understates recovery cost. As library breadth grows, more variants enter the template and re-run cost lines, while additional lot transitions introduce fresh calibration charges.

Cost attribution also depends on what can be observed. Kritharis et al. developed a fluorescent assay for real-time monitoring of transcription, translation, and key metabolite pools during CFPS optimization. That work illustrates the distinction between an endpoint yield and information about the reaction’s internal state. A ledger can show what the ambiguity costs and which missing records prevent a more precise diagnosis.

Where reagent transparency and documented formulations reduce the hidden cost burden

The practical response is to choose documented, lot-characterized reagents. This is the intervention that reaches across all four cost drivers, because it turns otherwise hidden differences into variables that can be examined. Information about pipetting behavior, viscosity, and minimum accurate dispense volume supports the dead volume audit. Published lot-level QC data lets teams compare the activity of a new lot with that of the previous lot before screening begins. Neither form of documentation eliminates overhead, but both reduce dependence on discovering problems through failed wells.

Template troubleshooting benefits from the same visibility. Knowing how a template interacts with a specific lysate formulation supports a systematic distinction between template and lysate problems. Records of how components interact during dilution and mixing also make it easier to find the cause of dispensing failures. An opaque formulation withholds that basis for diagnosis. When the endpoint signal cannot distinguish the possible causes, the team pays for uncertainty through re-expression.

Open-source extract recipes and shared kinetic models reflect the field’s use of common information to reduce the burden of reproducing results. OpenCFPS documents formulations openly, publishes lot-level QC data, and states a public per-mL price. Those features connect composition, lot behavior, and purchasing cost in a form that supports campaign accounting.

Kritharis et al. built a minimal CFPS platform that cost a fraction of commercial systems and gave comparable protein yields. That result supports judging engineered alternatives by how well they are shown to work and the full cost of a campaign, without assuming that the kit premium is needed to get that performance. For a team selecting a reagent system, the decision therefore extends beyond the price of filling a well. It also determines how much of the cost of obtaining an interpretable variant result will remain hidden.